全文获取类型
收费全文 | 94253篇 |
免费 | 6746篇 |
国内免费 | 424篇 |
专业分类
耳鼻咽喉 | 1118篇 |
儿科学 | 2369篇 |
妇产科学 | 1893篇 |
基础医学 | 11797篇 |
口腔科学 | 1985篇 |
临床医学 | 9513篇 |
内科学 | 21492篇 |
皮肤病学 | 1017篇 |
神经病学 | 8189篇 |
特种医学 | 3211篇 |
外国民族医学 | 2篇 |
外科学 | 14933篇 |
综合类 | 1284篇 |
现状与发展 | 1篇 |
一般理论 | 175篇 |
预防医学 | 7408篇 |
眼科学 | 2259篇 |
药学 | 6331篇 |
中国医学 | 161篇 |
肿瘤学 | 6285篇 |
出版年
2023年 | 413篇 |
2022年 | 605篇 |
2021年 | 1861篇 |
2020年 | 1127篇 |
2019年 | 1710篇 |
2018年 | 2085篇 |
2017年 | 1425篇 |
2016年 | 1628篇 |
2015年 | 1900篇 |
2014年 | 2873篇 |
2013年 | 4220篇 |
2012年 | 6050篇 |
2011年 | 6461篇 |
2010年 | 3698篇 |
2009年 | 3310篇 |
2008年 | 6102篇 |
2007年 | 6377篇 |
2006年 | 6113篇 |
2005年 | 6214篇 |
2004年 | 5730篇 |
2003年 | 5261篇 |
2002年 | 5153篇 |
2001年 | 1034篇 |
2000年 | 857篇 |
1999年 | 1017篇 |
1998年 | 1088篇 |
1997年 | 891篇 |
1996年 | 724篇 |
1995年 | 729篇 |
1994年 | 664篇 |
1993年 | 624篇 |
1992年 | 714篇 |
1991年 | 699篇 |
1990年 | 584篇 |
1989年 | 575篇 |
1988年 | 520篇 |
1987年 | 496篇 |
1986年 | 471篇 |
1985年 | 543篇 |
1984年 | 591篇 |
1983年 | 516篇 |
1982年 | 664篇 |
1981年 | 561篇 |
1980年 | 576篇 |
1979年 | 368篇 |
1978年 | 391篇 |
1977年 | 377篇 |
1976年 | 304篇 |
1975年 | 320篇 |
1974年 | 290篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
3.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
4.
5.
6.
7.
8.
Andrea Stracciolini Jennifer Luz Gregory Walker Nicholas M. Edwards Avery D. Faigenbaum Gregory D. Myer 《The Physician and sportsmedicine》2020,48(2):199-207
ABSTRACT
Objective
To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline. 相似文献9.
10.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献